A review of human vaccine research and development: Malaria
Abstract The last several years have seen significant progress in the development of vaccines against malaria. Most recently, proof-of-concept of vaccine-induced protection from malaria infection and disease was demonstrated in African children. Pursued by various groups and on many fronts, several...
Gespeichert in:
Veröffentlicht in: | Vaccine 2007-02, Vol.25 (9), p.1567-1580 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1580 |
---|---|
container_issue | 9 |
container_start_page | 1567 |
container_title | Vaccine |
container_volume | 25 |
creator | Girard, Marc P Reed, Zarifah H Friede, Martin Kieny, Marie Paule |
description | Abstract The last several years have seen significant progress in the development of vaccines against malaria. Most recently, proof-of-concept of vaccine-induced protection from malaria infection and disease was demonstrated in African children. Pursued by various groups and on many fronts, several other candidate vaccines are in early clinical trials. Yet, despite the optimism and promise, an effective malaria vaccine is not yet available, in part because of the lack of understanding of the types of immune responses needed for protection, added to the difficulty of identifying, selecting and producing the appropriate protective antigens from a parasite with a genome of well over five thousand genes and to the frequent need to enhance the immunogenicity of purified antigens through the use of novel adjuvants or delivery systems. Insufficient clinical trial capacity and normative research functions such as local ethical committee reviews also contribute to slow down the development process. This article attempts to summarize the state of the art of malaria vaccine development. |
doi_str_mv | 10.1016/j.vaccine.2006.09.074 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68935100</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X06010760</els_id><sourcerecordid>3379240931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c573t-e784bba6f249a21b5268e6341c079ea6296b13fcc7f0a0fc8fc7522a4d1ea6063</originalsourceid><addsrcrecordid>eNqFkl2L1DAUhoMo7uzqT1AK4t61npPmo1FQlsUvWPFCBe9Cmp6yGTvtmExH9t-bYQoDe7NXgeQ5b85538PYC4QKAdWbdbV33oeRKg6gKjAVaPGIrbDRdcklNo_ZCrgSpUD4fcbOU1oDgKzRPGVnqEHIWukVe3dVRNoH-ldMfXE7b9xYLLr5PpGL_rZwY1d0tKdh2m5o3L0tvrnBxeCesSe9GxI9X84L9uvTx5_XX8qb75-_Xl_dlF7qeleSbkTbOtVzYRzHVnLVkKoFetCGnOJGtVj33useHPS-6b2WnDvRYX4FVV-wy6PuNk5_Z0o7uwnJ0zC4kaY5WdWYWiLAgyAaqVBqk8FX98D1NMcxD2FRCo1KQoOZkkfKxymlSL3dxrBx8c4i2EMIdm0Xs-whBAvG5hBy3ctFfW431J2qFtcz8HoBXPJu6KMbfUgnrhHKaCkz9-HIUXY3hxRt8oFGT12I5He2m8KDrby_p-CHMIb86R-6o3Sa2iZuwf44bMxhYUABglZQ_wcp1bpg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547165081</pqid></control><display><type>article</type><title>A review of human vaccine research and development: Malaria</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Girard, Marc P ; Reed, Zarifah H ; Friede, Martin ; Kieny, Marie Paule</creator><creatorcontrib>Girard, Marc P ; Reed, Zarifah H ; Friede, Martin ; Kieny, Marie Paule</creatorcontrib><description>Abstract The last several years have seen significant progress in the development of vaccines against malaria. Most recently, proof-of-concept of vaccine-induced protection from malaria infection and disease was demonstrated in African children. Pursued by various groups and on many fronts, several other candidate vaccines are in early clinical trials. Yet, despite the optimism and promise, an effective malaria vaccine is not yet available, in part because of the lack of understanding of the types of immune responses needed for protection, added to the difficulty of identifying, selecting and producing the appropriate protective antigens from a parasite with a genome of well over five thousand genes and to the frequent need to enhance the immunogenicity of purified antigens through the use of novel adjuvants or delivery systems. Insufficient clinical trial capacity and normative research functions such as local ethical committee reviews also contribute to slow down the development process. This article attempts to summarize the state of the art of malaria vaccine development.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2006.09.074</identifier><identifier>PMID: 17045367</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Africa ; Allergy and Immunology ; Animals ; Antigens, Protozoan - chemistry ; Antigens, Protozoan - immunology ; Applied microbiology ; Biological and medical sciences ; Clinical trials ; Drug Design ; Fundamental and applied biological sciences. Psychology ; Genetic engineering ; Human protozoal diseases ; Humans ; Immunogenicity ; Infectious diseases ; Malaria ; Malaria Vaccines - chemistry ; Malaria Vaccines - immunology ; Malaria, Falciparum - prevention & control ; Medical research ; Medical sciences ; Merozoites ; Microbiology ; Parasites ; Parasitic diseases ; Plasmodium ; Plasmodium falciparum - growth & development ; Plasmodium falciparum - immunology ; Protozoal diseases ; R&D ; Research & development ; Research Design ; Sporozoites ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vector-borne diseases</subject><ispartof>Vaccine, 2007-02, Vol.25 (9), p.1567-1580</ispartof><rights>World Health Organization</rights><rights>2006 World Health Organization</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Elsevier Limited Feb 19, 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c573t-e784bba6f249a21b5268e6341c079ea6296b13fcc7f0a0fc8fc7522a4d1ea6063</citedby><cites>FETCH-LOGICAL-c573t-e784bba6f249a21b5268e6341c079ea6296b13fcc7f0a0fc8fc7522a4d1ea6063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X06010760$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18469755$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17045367$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Girard, Marc P</creatorcontrib><creatorcontrib>Reed, Zarifah H</creatorcontrib><creatorcontrib>Friede, Martin</creatorcontrib><creatorcontrib>Kieny, Marie Paule</creatorcontrib><title>A review of human vaccine research and development: Malaria</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract The last several years have seen significant progress in the development of vaccines against malaria. Most recently, proof-of-concept of vaccine-induced protection from malaria infection and disease was demonstrated in African children. Pursued by various groups and on many fronts, several other candidate vaccines are in early clinical trials. Yet, despite the optimism and promise, an effective malaria vaccine is not yet available, in part because of the lack of understanding of the types of immune responses needed for protection, added to the difficulty of identifying, selecting and producing the appropriate protective antigens from a parasite with a genome of well over five thousand genes and to the frequent need to enhance the immunogenicity of purified antigens through the use of novel adjuvants or delivery systems. Insufficient clinical trial capacity and normative research functions such as local ethical committee reviews also contribute to slow down the development process. This article attempts to summarize the state of the art of malaria vaccine development.</description><subject>Africa</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antigens, Protozoan - chemistry</subject><subject>Antigens, Protozoan - immunology</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Drug Design</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genetic engineering</subject><subject>Human protozoal diseases</subject><subject>Humans</subject><subject>Immunogenicity</subject><subject>Infectious diseases</subject><subject>Malaria</subject><subject>Malaria Vaccines - chemistry</subject><subject>Malaria Vaccines - immunology</subject><subject>Malaria, Falciparum - prevention & control</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Merozoites</subject><subject>Microbiology</subject><subject>Parasites</subject><subject>Parasitic diseases</subject><subject>Plasmodium</subject><subject>Plasmodium falciparum - growth & development</subject><subject>Plasmodium falciparum - immunology</subject><subject>Protozoal diseases</subject><subject>R&D</subject><subject>Research & development</subject><subject>Research Design</subject><subject>Sporozoites</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vector-borne diseases</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkl2L1DAUhoMo7uzqT1AK4t61npPmo1FQlsUvWPFCBe9Cmp6yGTvtmExH9t-bYQoDe7NXgeQ5b85538PYC4QKAdWbdbV33oeRKg6gKjAVaPGIrbDRdcklNo_ZCrgSpUD4fcbOU1oDgKzRPGVnqEHIWukVe3dVRNoH-ldMfXE7b9xYLLr5PpGL_rZwY1d0tKdh2m5o3L0tvrnBxeCesSe9GxI9X84L9uvTx5_XX8qb75-_Xl_dlF7qeleSbkTbOtVzYRzHVnLVkKoFetCGnOJGtVj33useHPS-6b2WnDvRYX4FVV-wy6PuNk5_Z0o7uwnJ0zC4kaY5WdWYWiLAgyAaqVBqk8FX98D1NMcxD2FRCo1KQoOZkkfKxymlSL3dxrBx8c4i2EMIdm0Xs-whBAvG5hBy3ctFfW431J2qFtcz8HoBXPJu6KMbfUgnrhHKaCkz9-HIUXY3hxRt8oFGT12I5He2m8KDrby_p-CHMIb86R-6o3Sa2iZuwf44bMxhYUABglZQ_wcp1bpg</recordid><startdate>20070219</startdate><enddate>20070219</enddate><creator>Girard, Marc P</creator><creator>Reed, Zarifah H</creator><creator>Friede, Martin</creator><creator>Kieny, Marie Paule</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20070219</creationdate><title>A review of human vaccine research and development: Malaria</title><author>Girard, Marc P ; Reed, Zarifah H ; Friede, Martin ; Kieny, Marie Paule</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c573t-e784bba6f249a21b5268e6341c079ea6296b13fcc7f0a0fc8fc7522a4d1ea6063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Africa</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antigens, Protozoan - chemistry</topic><topic>Antigens, Protozoan - immunology</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Drug Design</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genetic engineering</topic><topic>Human protozoal diseases</topic><topic>Humans</topic><topic>Immunogenicity</topic><topic>Infectious diseases</topic><topic>Malaria</topic><topic>Malaria Vaccines - chemistry</topic><topic>Malaria Vaccines - immunology</topic><topic>Malaria, Falciparum - prevention & control</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Merozoites</topic><topic>Microbiology</topic><topic>Parasites</topic><topic>Parasitic diseases</topic><topic>Plasmodium</topic><topic>Plasmodium falciparum - growth & development</topic><topic>Plasmodium falciparum - immunology</topic><topic>Protozoal diseases</topic><topic>R&D</topic><topic>Research & development</topic><topic>Research Design</topic><topic>Sporozoites</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Girard, Marc P</creatorcontrib><creatorcontrib>Reed, Zarifah H</creatorcontrib><creatorcontrib>Friede, Martin</creatorcontrib><creatorcontrib>Kieny, Marie Paule</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Girard, Marc P</au><au>Reed, Zarifah H</au><au>Friede, Martin</au><au>Kieny, Marie Paule</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A review of human vaccine research and development: Malaria</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2007-02-19</date><risdate>2007</risdate><volume>25</volume><issue>9</issue><spage>1567</spage><epage>1580</epage><pages>1567-1580</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract The last several years have seen significant progress in the development of vaccines against malaria. Most recently, proof-of-concept of vaccine-induced protection from malaria infection and disease was demonstrated in African children. Pursued by various groups and on many fronts, several other candidate vaccines are in early clinical trials. Yet, despite the optimism and promise, an effective malaria vaccine is not yet available, in part because of the lack of understanding of the types of immune responses needed for protection, added to the difficulty of identifying, selecting and producing the appropriate protective antigens from a parasite with a genome of well over five thousand genes and to the frequent need to enhance the immunogenicity of purified antigens through the use of novel adjuvants or delivery systems. Insufficient clinical trial capacity and normative research functions such as local ethical committee reviews also contribute to slow down the development process. This article attempts to summarize the state of the art of malaria vaccine development.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>17045367</pmid><doi>10.1016/j.vaccine.2006.09.074</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2007-02, Vol.25 (9), p.1567-1580 |
issn | 0264-410X 1873-2518 |
language | eng |
recordid | cdi_proquest_miscellaneous_68935100 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Africa Allergy and Immunology Animals Antigens, Protozoan - chemistry Antigens, Protozoan - immunology Applied microbiology Biological and medical sciences Clinical trials Drug Design Fundamental and applied biological sciences. Psychology Genetic engineering Human protozoal diseases Humans Immunogenicity Infectious diseases Malaria Malaria Vaccines - chemistry Malaria Vaccines - immunology Malaria, Falciparum - prevention & control Medical research Medical sciences Merozoites Microbiology Parasites Parasitic diseases Plasmodium Plasmodium falciparum - growth & development Plasmodium falciparum - immunology Protozoal diseases R&D Research & development Research Design Sporozoites Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vector-borne diseases |
title | A review of human vaccine research and development: Malaria |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T07%3A01%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20review%20of%20human%20vaccine%20research%20and%20development:%20Malaria&rft.jtitle=Vaccine&rft.au=Girard,%20Marc%20P&rft.date=2007-02-19&rft.volume=25&rft.issue=9&rft.spage=1567&rft.epage=1580&rft.pages=1567-1580&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2006.09.074&rft_dat=%3Cproquest_cross%3E3379240931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1547165081&rft_id=info:pmid/17045367&rft_els_id=S0264410X06010760&rfr_iscdi=true |